Relevance of the application of pharmacokinetic-pharmacodynamic modelling concepts in drug development. The 'wooden shoe' paradigm

Clinical Pharmacokinetics

Volumn 32, Issue 4, 1997, Pages 259-267

  Breimer, D D ^a   Danhof, M ^a  

^a LEIDEN UNIVERSITY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ALFENTANIL; BENZODIAZEPINE; FENTANYL; FLUMAZENIL; MIDAZOLAM; NIFEDIPINE; REMIFENTANIL; SUFENTANIL; TEMAZEPAM;

CLINICAL TRIAL; DOSE CALCULATION; DRUG BLOOD LEVEL; DRUG DEVELOPMENT; DRUG METABOLISM; DRUG POTENCY; ELECTROENCEPHALOGRAM; HUMAN; HYPERTENSION; MODEL; NONHUMAN; PHARMACODYNAMICS; PHARMACOKINETICS; PRIORITY JOURNAL; REVIEW;

EID: 0030890279     PISSN: 03125963     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003088-199732040-00001     Document Type: Review

References (35)

1. 1. CJ Boxtel Van NHG Holford M Danhof 1992 The in vivo study of drug action: concepts and applications of kinetic-dynamic modelling Elsevier Science Publishers Amsterdam Van Boxtel CJ, Holford NHG, Danhof M. The in vivo study of drug action: concepts and applications of kinetic-dynamic modelling. Amsterdam: Elsevier Science Publishers, 1992
2. 2. H Derendorf G Hochhaus 1995 Handbook of pharmacokinetic/ pharmacodynamic correlation CRC Press Boca Raton Derendorf H, Hochhaus G. Handbook of pharmacokinetic/ pharmacodynamic correlation. Boca Raton: CRC Press, 1995
3. 3. A Yacobi JP Skelly VP Shah 1993 Integration of pharmacokinetics, pharmacodynamics and toxicokinetics in rational drug development Plenum Press New York Yacobi A, Skelly JP, Shah VP, et al. Integration of pharmacokinetics, pharmacodynamics and toxicokinetics in rational drug development. New York: Plenum Press, 1993
4. 4. M Rowland L Aarons 1992 New strategies in drug development and clinical evaluation: the population approach Office for Offical Publications of the European Communities Luxembourg Rowland M, Aarons L, editors. New strategies in drug development and clinical evaluation: the population approach. Luxembourg: Office for Offical Publications of the European Communities, 1992
5. 5. LB Sheiner DR Stanski S Vozeh 1979 Simultaneous modelling of pharmacokinetics and pharmacodynamics: application to d-tubocurarine Clin Pharmacol Ther 25 358 71 761446 1:CAS:528:DyaE1MXhsl2qsro%3D Sheiner LB, Stanski DR, Vozeh S, et al. Simultaneous modelling of pharmacokinetics and pharmacodynamics: application to d-tubocurarine. Clin Pharmacol Ther 1979; 25: 358–71
6. 6. E Fuseau LB Sheiner 1984 Simultaneous modeling of pharmacokinetics and pharmacodynamics with a nonparametric pharmacodynamic model Clin Pharmacol Ther 35 733 41 6329584 10.1038/clpt.1984.104 1:CAS:528:DyaL2cXksVyit7s%3D Fuseau E, Sheiner LB. Simultaneous modeling of pharmacokinetics and pharmacodynamics with a nonparametric pharmacodynamic model. Clin Pharmacol Ther 1984; 35: 733–41
7. 7. J Unadkat F Bartha LB Sheiner 1986 Simultaneous modelling of pharmacokinetics and pharmacodynamics with nonparamet-ric kinetic and dynamic models Clin Pharmacol Ther 40 86 93 3720181 10.1038/clpt.1986.143 1:CAS:528:DyaL28XkvFSkt70%3D Unadkat J, Bartha F, Sheiner LB. Simultaneous modelling of pharmacokinetics and pharmacodynamics with nonparamet-ric kinetic and dynamic models. Clin Pharmacol Ther 1986; 40: 86–93
8. 8. P Veng-Pedersen JW Mandema M Danhof 1991 A system approach to pharmacodynamics III: an algorithm and computer program ‘COLAPS’ for pharmacodynamic modeling J Pharm Sci 80 86 93 Veng-Pedersen P, Mandema JW, Danhof M. A system approach to pharmacodynamics III: an algorithm and computer program ‘COLAPS’ for pharmacodynamic modeling. J Pharm Sci 1991; 80: 86–93
9. 9. P Veng-Pedersen NB Modi 1992 Pharmacodynamic system analysis of the biophase level predictor and the transduction function J Pharm Sci 81 925 34 1432642 10.1002/jps.2600810918 1:CAS:528:DyaK38XlvVCiu74%3D Veng-Pedersen P, Modi NB. Pharmacodynamic system analysis of the biophase level predictor and the transduction function. J Pharm Sci 1992; 81: 925–34
10. 10. NL Dayneka V Garg WJ Jusko 1993 Comparison of four basic models of indirect pharmacodynamic responses J Pharmacokinet Biopharm 21 457 78 8133465 1:CAS:528:DyaK2cXitlGhsb0%3D Dayneka NL, Garg V, Jusko WJ. Comparison of four basic models of indirect pharmacodynamic responses. J Pharmacokinet Biopharm 1993; 21: 457–78
11. 11. WJ Jusko HC Ko 1994 Physiologic indirect response models characterize diverse types of pharmacodynamic effects Clin Pharmacol Ther 56 406 19 7955802 10.1038/clpt.1994.155 1:CAS:528:DyaK2MXitFWqtb8%3D Jusko WJ, Ko HC. Physiologic indirect response models characterize diverse types of pharmacodynamic effects. Clin Pharmacol Ther 1994; 56: 406–19
12. 12. J Dingemanse M Danhof DD Breimer 1988 Pharmacokinetic-pharmacodynamic modelling of CNS drug effects Pharmacol Ther 38 1 52 3293088 10.1016/0163-7258(88)90101-5 1:CAS:528:DyaL1cXltVeqt70%3D Dingemanse J, Danhof M, Breimer DD. Pharmacokinetic-pharmacodynamic modelling of CNS drug effects. Pharmacol Ther 1988; 38: 1–52
13. 13. JW Blue WA Colburn 1996 Efficacy measures: surrogates or clinical outcomes? J Clin Pharmacol 36 767 70 8889896 1:STN:280:DyaK2s%2FksVyhtw%3D%3D Blue JW, Colburn WA. Efficacy measures: surrogates or clinical outcomes? J Clin Pharmacol 1996; 36: 767–70
14. 14. CC Peck WH Barr LZ Benet 1992 Opportunities for integration of pharmacokinetics, pharmacodynamics and toxicokinetics in rational drug development Clin Pharmacol Ther 51 465 73 1563216 10.1038/clpt.1992.47 1:STN:280:DyaK383isVGlsw%3D%3D Peck CC, Barr WH, Benet LZ, et al. Opportunities for integration of pharmacokinetics, pharmacodynamics and toxicokinetics in rational drug development. Clin Pharmacol Ther 1992 Apr; 51: 465–73
15. 15. R Lieberman J McMichael 1996 Role of pharmacokinetic-pharmacodynamic principles in rational and cost-effective drug development Ther Drug Monit 18 423 8 8857562 10.1097/00007691-199608000-00019 1:CAS:528:DyaK28Xlt1Ggsb8%3D Lieberman R, McMichael J. Role of pharmacokinetic-pharmacodynamic principles in rational and cost-effective drug development. Ther Drug Monit 1996; 18: 423–8
16. 16. M Danhof JW Mandema A Hoogerkamp 1993 Pharmacokinetic-pharmacodynamic modelling in pre-clinical investigations: principles and perspectives Eur J Drug Metab Pharmacokinet 18 41 7 8335038 10.1007/BF03220007 1:CAS:528:DyaK3sXlslentLs%3D Danhof M, Mandema JW, Hoogerkamp A, et al. Pharmacokinetic-pharmacodynamic modelling in pre-clinical investigations: principles and perspectives. Eur J Drug Metab Pharmacokinet 1993; 18: 41–7
17. 17. R Nagashima R O’Reilly G Levy 1969 Kinetics of pharmacologic effects in man: the anticoagulant action of warfarin Clin Pharmacol Ther 10 22 35 5765183 1:CAS:528:DyaF1MXls1ahtg%3D%3D Nagashima R, O’Reilly R, Levy G. Kinetics of pharmacologic effects in man: the anticoagulant action of warfarin. Clin Pharmacol Ther 1969; 10: 22–35
18. 18. A Yacobi LB Wingard G Levy 1974 Comparative pharmacokinetics of coumarin anticoagulants X: relationship between distribution, elimination and anticoagulant action of warfarin J Pharm Sci 63 868 72 4851098 10.1002/jps.2600630613 1:CAS:528:DyaE2cXkslantb8%3D Yacobi A, Wingard LB, Levy G. Comparative pharmacokinetics of coumarin anticoagulants X: relationship between distribution, elimination and anticoagulant action of warfarin. J Pharm Sci 1974; 63: 868–72
19. 19. JW Mandema E Tukker M Danhof 1992 In vivo characterization of the pharmacodynamic interaction of a benzodiazepine agonist and antagonist: midazolam and flumazenil J Pharmacol Exp Ther 260 36 44 1309878 1:CAS:528:DyaK38XnsFOhug%3D%3D Mandema JW, Tukker E, Danhof M. In vivo characterization of the pharmacodynamic interaction of a benzodiazepine agonist and antagonist: midazolam and flumazenil. J Pharmacol Exp Ther 1992; 260: 36–44
20. 20. LTM Breimer AGL Burm M Danhof 1991 Pharmacokineticpharmacodynamic modelling of the interaction between flumazenil and midazolam in volunteers by aperiodic EEG analysis Clin Pharmacokinet 20 497 508 2044333 10.2165/00003088-199120060-00006 1:CAS:528:DyaK3MXmt1ehs7k%3D Breimer LTM, Burm AGL, Danhof M, et al. Pharmacokineticpharmacodynamic modelling of the interaction between flumazenil and midazolam in volunteers by aperiodic EEG analysis. Clin Pharmacokinet 1991; 20: 497–508
21. 21. Struyker Boudier HAJ, Van Essen H, Smits JFM. Can reflex increase in heart rate and cardiac output of arteriolar vasodilators in hypertension be avoided? [abstract no. 429]. First European Meeting on Hypertension; 1983 May 24-Jun 1: Milan
22. 22. CH Kleinbloesem P Brummelen Van M Danhof 1987 Rate of increase in the plasma concentration of nifedipine as a major determinant of its hemodynamic effects in humans Clin Pharmacol Ther 41 20 30 10.1038/clpt.1987.5 Kleinbloesem CH, Van Brummelen P, Danhof M, et al. Rate of increase in the plasma concentration of nifedipine as a major determinant of its hemodynamic effects in humans. Clin Pharmacol Ther 1987; 41: 20–30
23. 23. J Urquhart 1994 Role of patient compliance in clinical pharmacokinetics: review of recent research Clin Pharmacokinet 27 202 15 7988102 10.2165/00003088-199427030-00004 1:STN:280:DyaK2M%2FnvFOitw%3D%3D Urquhart J. Role of patient compliance in clinical pharmacokinetics: review of recent research. Clin Pharmacokinet 1994; 27: 202–15
24. 24. JW Mandema LN Sansom MC Dios-Vieitez 1991 Pharmacokinetic-pharmacodynamic modelling of the EEG effect of benzodiazepines: correlation with receptor binding and anti-convulsant activity J Pharmacol Exp Ther 257 472 8 1850477 1:CAS:528:DyaK3MXisVSnu7k%3D Mandema JW, Sansom LN, Dios-Vieitez MC, et al. Pharmacokinetic-pharmacodynamic modelling of the EEG effect of benzodiazepines: correlation with receptor binding and anti-convulsant activity. J Pharmacol Exp Ther 1991; 257: 472–8
25. 25. JW Mandema MT Kuck M Danhof 1992 Differences in intrinsic efficacy of benzodiazepines are reflected in their concentration EEG effect relationship Br J Pharmacol 105 164 70 1350744 10.1111/j.1476-5381.1992.tb14229.x 1:CAS:528:DyaK38XhvVOqtLs%3D Mandema JW, Kuck MT, Danhof M. Differences in intrinsic efficacy of benzodiazepines are reflected in their concentration EEG effect relationship. Br J Pharmacol 1992; 105: 164–70
26. 26. RAA Mathôt BCFM Aarsen Van den W Soudijn 1995 Pharmacokinetic-pharmacodynamic modelling of the cardiovascular effects of R-and S-H 6 phenylisopropyl-adenosine in conscious normotensive rats J Pharmacol Exp Ther 273 405 14 7714796 Mathôt RAA, Van den Aarsen BCFM, Soudijn W, et al. Pharmacokinetic-pharmacodynamic modelling of the cardiovascular effects of R-and S-H 6 phenylisopropyl-adenosine in conscious normotensive rats. J Pharmacol Exp Ther 1995; 273: 405–14
27. 27. G Levy 1993 The case for preclinical pharmacodynamics A Yacobi JP Skelly VP Shah Integration of pharmacokinetics, pharmacodynamics and toxicokinetics in rational drug development Plenum Press New York 7 13 Levy G. The case for preclinical pharmacodynamics. In: Yacobi A, Skelly JP, Shah VP, et al., editors. Integration of pharmacokinetics, pharmacodynamics and toxicokinetics in rational drug development. New York: Plenum Press, 1993: 7–13
28. 28. JM Collins 1993 Use of pharmacokinetics and pharmacodynamics in preclinical studies to guide dosage escalation schemes in phase I studies of anticancer drugs A Yacobi JP Skelly VP Shah Integration of pharmacokinetics, pharmacodynamics and toxicokinetics in rational drug development Plenum Press New York 49 54 Collins JM. Use of pharmacokinetics and pharmacodynamics in preclinical studies to guide dosage escalation schemes in phase I studies of anticancer drugs. In: Yacobi A, Skelly JP, Shah VP, et al., editors. Integration of pharmacokinetics, pharmacodynamics and toxicokinetics in rational drug development. New York: Plenum Press, 1993: 49–54
29. 29. TD Egan CF Minto DJ Hermann 1996 Remifentanil versus alfentanil: comparative pharmacokinetics and pharmacodynamics in healthy adult male volunteers Anesthesiology 84 821 33 8638836 10.1097/00000542-199604000-00009 1:CAS:528:DyaK28Xis1Wntbw%3D Egan TD, Minto CF, Hermann DJ, et al. Remifentanil versus alfentanil: comparative pharmacokinetics and pharmacodynamics in healthy adult male volunteers. Anesthesiology 1996; 84: 821–33
30. 30. AL Steveninck Van S Verver RC Schoemaker 1992 Effects of temazepam on saccadic eye movements: concentration-effect relationships in individual healthy volunteers Clin Pharmacol Ther 52 402 8 1424412 10.1038/clpt.1992.162 Van Steveninck AL, Verver S, Schoemaker RC, et al. Effects of temazepam on saccadic eye movements: concentration-effect relationships in individual healthy volunteers. Clin Pharmacol Ther 1992; 52; 402–8
31. 31. CH Kleinbloesem P Brummelen Van J Harten Van 1985 Nifedipine: influence of renal function on pharmacokinetic/ haemodynamic relationship Clin Pharmacol Ther 37 563 74 3987180 10.1038/clpt.1985.89 1:STN:280:DyaL2M7nvVSisA%3D%3D Kleinbloesem CH, Van Brummelen P, Van Harten J, et al. Nifedipine: influence of renal function on pharmacokinetic/ haemodynamic relationship. Clin Pharmacol Ther 1985; 37: 563–74
32. 32. CH Kleinbloesem J Harten Van JHP Wilson 1986 Nifedipine: kinetics and dynamics in patients with liver cirrhosis after intravenous and oral administration Clin Pharmacol Ther 40 21 8 3720176 10.1038/clpt.1986.134 1:STN:280:DyaL283ks1Sgsw%3D%3D Kleinbloesem CH, Van Harten J, Wilson JHP, et al. Nifedipine: kinetics and dynamics in patients with liver cirrhosis after intravenous and oral administration. Clin Pharmacol Ther 1986; 40: 21–8
33. 33. Peck CC. How golden are the eggs? Inaugural lecture held on the occasion of the Boerhaave Professorship at Leiden University, The Netherlands, 1994
34. 34. LB Sheiner 1991 The intellectual health of clinical drug evaluation Clin Pharmacol Ther 50 409 10.1038/clpt.1991.97 Sheiner LB. The intellectual health of clinical drug evaluation. Clin Pharmacol Ther 1991; 50; 409
35. 35. Steimer JL, Kawai, R, Charnick S, et al. Physiological pharmacokinetic/pharmacodynamic (PB-PK/PD) models in drug development? Proceedings of the 2nd International Symposium on Measurement and Kinetics of In Vivo Drug Effects; 1994 Apr 14–16; Noordwijkerhout, The Netherlands. Leiden: Leiden/Amsterdam Center for Drug Research, 1994